Correlation Between Crispr Therapeutics and Caribou Biosciences

Can any of the company-specific risk be diversified away by investing in both Crispr Therapeutics and Caribou Biosciences at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Crispr Therapeutics and Caribou Biosciences into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Crispr Therapeutics AG and Caribou Biosciences, you can compare the effects of market volatilities on Crispr Therapeutics and Caribou Biosciences and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Crispr Therapeutics with a short position of Caribou Biosciences. Check out your portfolio center. Please also check ongoing floating volatility patterns of Crispr Therapeutics and Caribou Biosciences.

Diversification Opportunities for Crispr Therapeutics and Caribou Biosciences

0.75

Correlation Coefficient

Crispr Therapeutics  Caribou Biosciences

Poor diversification

The 3 months correlation between Crispr and Caribou is 0.75. Overlapping area represents the amount of risk that can be diversified away by holding Crispr Therapeutics AG and Caribou Biosciences in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Caribou Biosciences and Crispr Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Crispr Therapeutics AG are associated (or correlated) with Caribou Biosciences. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Caribou Biosciences has no effect on the direction of Crispr Therapeutics i.e., Crispr Therapeutics and Caribou Biosciences go up and down completely randomly.

Pair Corralation between Crispr Therapeutics and Caribou Biosciences

Given the investment horizon of 90 days Crispr Therapeutics AG is expected to under-perform the Caribou Biosciences. But the stock apears to be less risky and, when comparing its historical volatility, Crispr Therapeutics AG is 1.28 times less risky than Caribou Biosciences. The stock trades about -0.21 of its potential returns per unit of risk. The Caribou Biosciences is currently generating about -0.15 of returns per unit of risk over similar time horizon. If you would invest  202.00  in Caribou Biosciences on September 27, 2024 and sell it today you would lose (33.00) from holding Caribou Biosciences or give up 16.34% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Crispr Therapeutics AG  vs.  Caribou Biosciences

Crispr Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Crispr Therapeutics AG has generated negative risk-adjusted returns adding no value to investors with long positions. Even with latest unfluctuating performance, the Stock's basic indicators remain invariable and the latest agitation on Wall Street may also be a sign of long-running gains for the enterprise retail investors.

Caribou Biosciences

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Caribou Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's fundamental drivers remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors.

Pair Trading with Crispr Therapeutics and Caribou Biosciences

The main advantage of trading using opposite Crispr Therapeutics and Caribou Biosciences positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Crispr Therapeutics position performs unexpectedly, Caribou Biosciences can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Caribou Biosciences will offset losses from the drop in Caribou Biosciences' long position.

The idea behind Crispr Therapeutics AG and Caribou Biosciences pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.